# A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway

> **NCT02544997** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 5 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Poziotinib

## Key facts

- **NCT ID:** NCT02544997
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2020-02
- **Final completion:** 2020-02
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02544997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02544997, "A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02544997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*